Andere talen Myriad Genetics, Inc.

Aandelen

MYGN

US62855J1043

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 02-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
19,22 ^USD	-1,28%		+6,90%	+0,42%

27/02	Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024
27/02	Myriad Genetics, Inc. Geeft omzetrichtlijnen voor het eerste kwartaal van 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024	30/04
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel Prenatal Screen	17/04
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor	17/04
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen	16/04
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing	09/04
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing	09/04
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date	22/03
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date	22/03
Myriad Genetics Gets US Patent for SneakPeek Snap Device	20/03
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device	20/03
Myriad: Q4 Earnings Snapshot	27/02
Earnings Flash (MYGN) MYRIAD GENETICS Reports Q4 EPS $0.04, vs. Street Est of $0.01	27/02
(MYGN) MYRIAD GENETICS Forecasts 2024 Revenue Range $820M - $840M	27/02
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance	27/02
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance	27/02
Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024	27/02
Myriad Genetics, Inc. Updates Revenue Guidance for the Fiscal Year 2024	27/02
Myriad Genetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Myriad Genetics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3	27/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Myriad Genetics, Inc.

Aandelen

MYGN

US62855J1043

Andere talen

Filters